Series B Biotech companies in New York

Comprehensively mapping and decoding the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes

• Series B
• 173 employees
• Founded 2019

Lifebit powers the federated infrastructure behind national-scale biomedical research. Our platform enables pharma, biobanks, and governments to analyze the world's most sensitive health data — without the data ever leaving its source.Genomics England runs on Lifebit. So do ten of the world's largest biobanks, and research programs spanning the UK, US, and Asia.We built the federated Trusted Research Environment (TRE) from first principles around the ONS Five Safes framework: data stays at source, sovereignty stays with the data controller, and every output passes through an airlock. It's what makes population-scale genomics, federated multi-omic analysis, and cross-border biomedical AI possible without compromising patient trust.For the pharma companies accelerating discovery. For the biobanks safeguarding a generation of consented data. For the governments treating health data as sovereign infrastructure — Lifebit is the operating layer.

• Series B
• 67 employees
• Founded 2017

Evvy is unlocking precision women’s healthcare through novel, overlooked female biomarkers — starting with the vaginal microbiome. Backed by leading healthcare investors such as General Catalyst, Left Lane Capital, and LabCorp, the Evvy team includes leading OB/GYNs and vaginal microbiome researchers with decades of experience at organizations like UCSF, Stanford, Harvard, Cleveland Clinic, and more. Evvy is one of the fastest growing women’s health companies in the US — enabling us to deliver innovative, high quality care while scaling novel R&D to unlock a new, data-driven future in women’s health.Evvy’s Vaginal Health Test is the first at-home vaginal microbiome test to use metagenomic sequencing to tell you what’s up down there, why it matters, and what you can do about it. Evvy’s larger platform is the first vaginal healthcare service to bring together state-of-the-art testing, precision clinical care, and 1:1 coaching to give women and people with vaginas the care they deserve. Through this platform, Evvy is building real-world datasets that can transform our understanding of complex female health conditions. Imagine a world where female health is finally understood: where risks are detected early and precisely; conditions are defined with specificity and nuance; and diseases are treated with personalization and care. That’s the world that Evvy is pioneering.

• Series B
• 63 employees
• Founded 2020

Helaina is a biotech company pushing the boundaries of what food can do for health.

• Series B
• 50 employees
• Founded 2019

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

• Series B
• 33 employees
• Founded 2014